Publisher
West-Japanese Society of Orthopedics & Traumatology
Reference6 articles.
1. 1) Demetri, G. D., et al.: Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a PhaseⅢ Randomized Multicenter Clinical Trial. J. Clin. Oncol., 34: 786-793, 2016.
2. 2) D'Incalci, M., Galmarini, C. M.: A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther., 9: 2157-2163, 2010.
3. 3) Kobayashi, H., et al.: Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. Cancer, 126: 1253-1263, 2020.
4. 4) Le Cesne, A., et al.: A randomized phase Ⅲ trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann. Oncol., 32: 1034-1044, 2021.
5. 5) Le Cesne, A., et al.: Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur. J. Cancer, 51: 742-750, 2015.